↓ Skip to main content

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Overview of attention for article published in Blood Cancer Journal, February 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 1,168)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
51 news outlets
twitter
13 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
61 Mendeley